{"log_id": 4297321385559411445, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998634, "min": 0.996363}, "location": {"width": 65, "top": 174, "height": 28, "left": 84}, "words": "于3%"}, {"probability": {"variance": 1.8e-05, "average": 0.998001, "min": 0.976933}, "location": {"width": 800, "top": 201, "height": 51, "left": 133}, "words": "也可见到细胞溶解性、胆汁淤积性肝炎或肝衰竭病例,其中有些是致死性的"}, {"probability": {"variance": 1e-06, "average": 0.999344, "min": 0.997947}, "location": {"width": 131, "top": 267, "height": 33, "left": 94}, "words": "【禁忌】"}, {"probability": {"variance": 4.6e-05, "average": 0.997449, "min": 0.968482}, "location": {"width": 489, "top": 306, "height": 42, "left": 134}, "words": "对本药活性物质或任何赋形剂成份过敏者禁用"}, {"probability": {"variance": 3e-06, "average": 0.999069, "min": 0.994945}, "location": {"width": 131, "top": 361, "height": 32, "left": 95}, "words": "【注意事项】"}, {"probability": {"variance": 1.2e-05, "average": 0.997761, "min": 0.980726}, "location": {"width": 923, "top": 391, "height": 52, "left": 136}, "words": "已有报道,本品治疗的患者有明显的左心室射血分数(LVEF)减少,以及充血性心力衰"}, {"probability": {"variance": 0.001263, "average": 0.989709, "min": 0.817994}, "location": {"width": 970, "top": 440, "height": 51, "left": 90}, "words": "竭的症状。在动物实验中显示,c-Abl酶抑制剂能引起心肌细胞的强烈反应,大鼠的致癌性试"}, {"probability": {"variance": 2e-06, "average": 0.998969, "min": 0.99198}, "location": {"width": 947, "top": 488, "height": 52, "left": 89}, "words": "验中,已有心肌疾病的报道。因此,对有心血管疾病危险或有心脏疾病的患者应严密监测"}, {"probability": {"variance": 2.5e-05, "average": 0.998428, "min": 0.967374}, "location": {"width": 972, "top": 536, "height": 50, "left": 91}, "words": "应用本品治疗的老年患者或有心脏疾病史的患者,应首先测左心室射血分数(LVEF),在治"}, {"probability": {"variance": 0, "average": 0.999523, "min": 0.997152}, "location": {"width": 801, "top": 587, "height": 47, "left": 91}, "words": "疗期间,患者有明显的心衰症状应全面检查,并根据临床症状进行相应治疗"}, {"probability": {"variance": 2e-06, "average": 0.999237, "min": 0.992027}, "location": {"width": 923, "top": 631, "height": 49, "left": 142}, "words": "甲磺酸伊马替尼治疗第一个月宜每周查一次全血象,第二个月每两周查一次,以后则视"}, {"probability": {"variance": 0.003364, "average": 0.9846, "min": 0.672868}, "location": {"width": 970, "top": 679, "height": 52, "left": 93}, "words": "需要而定(如每2--3个月查一次)。若发生严重中性粒细胞或血小板减少,应调整剂量(见"}, {"probability": {"variance": 0.000639, "average": 0.983416, "min": 0.925757}, "location": {"width": 143, "top": 748, "height": 29, "left": 103}, "words": "【用法用量】)"}, {"probability": {"variance": 4e-06, "average": 0.999206, "min": 0.988582}, "location": {"width": 924, "top": 776, "height": 51, "left": 143}, "words": "开始治疗前应检查肝功能(转氨酶、胆红素和碱性磷酸酶),随后每月查一次或根据临床"}, {"probability": {"variance": 6e-06, "average": 0.998672, "min": 0.989856}, "location": {"width": 970, "top": 823, "height": 52, "left": 97}, "words": "情况决定,必要时应调整剂量。对轻、中、重肝功能损害患者应监测其血象和肝酶。(见【用"}, {"probability": {"variance": 6e-06, "average": 0.998732, "min": 0.988872}, "location": {"width": 969, "top": 871, "height": 50, "left": 97}, "words": "法用量】,【不良反应】和【药代动力学】)。肝功能衰竭患者甲磺酸伊马替尼的暴露量可能会"}, {"probability": {"variance": 7.5e-05, "average": 0.997606, "min": 0.944436}, "location": {"width": 969, "top": 918, "height": 52, "left": 99}, "words": "增加,肝功损害者慎用本品。严重肝功能衰竭者在认真进行风险一效益比评估后,才能使用"}, {"probability": {"variance": 0.001065, "average": 0.990573, "min": 0.796674}, "location": {"width": 971, "top": 967, "height": 51, "left": 100}, "words": "甲磺酸伊马替尼(见【用法用量】)。应谨记GIST患者可能有肝转移,从而增加肝功能的损"}, {"probability": {"variance": 6e-06, "average": 0.998527, "min": 0.989377}, "location": {"width": 970, "top": 1016, "height": 51, "left": 100}, "words": "害。伊马替尼与大剂量化疗药合用时,已观察到一过性的肝毒性,患者转氨酶升高并出现高"}, {"probability": {"variance": 0.000426, "average": 0.994459, "min": 0.870415}, "location": {"width": 972, "top": 1062, "height": 58, "left": 101}, "words": "胆红素血症。化疗合用伊马替尼时,可能引起肝功能不全,要注意监测肝功能(见【不良反"}, {"probability": {"variance": 3e-06, "average": 0.998118, "min": 0.996325}, "location": {"width": 46, "top": 1135, "height": 26, "left": 104}, "words": "应】"}, {"probability": {"variance": 0.000171, "average": 0.995576, "min": 0.921084}, "location": {"width": 920, "top": 1159, "height": 51, "left": 154}, "words": "同时服用甲磺酸伊马替尼和CYP3A4诱导剂(见【药物相互作用】)可显著降低伊马替"}, {"probability": {"variance": 6e-06, "average": 0.998889, "min": 0.986975}, "location": {"width": 970, "top": 1208, "height": 52, "left": 105}, "words": "尼的总暴露量,因此增加潜在治疗失败的危险。因此应避免甲磺酸伊马替尼与CYP3A4诱导"}, {"probability": {"variance": 1.4e-05, "average": 0.997815, "min": 0.980755}, "location": {"width": 970, "top": 1256, "height": 53, "left": 106}, "words": "剂合用。甲磺酸伊马替尼与利福平或其它强CYP3A4诱导剂,酮康唑或其他强CYP3A4抑制"}, {"probability": {"variance": 2.3e-05, "average": 0.997067, "min": 0.975929}, "location": {"width": 971, "top": 1304, "height": 54, "left": 107}, "words": "剂,治疗窗狭窄的CYP3A4底物(如环孢素或匹莫齐特)或治疗窗狭窄的CYP2C9底物(如华"}, {"probability": {"variance": 0.000665, "average": 0.992045, "min": 0.885386}, "location": {"width": 710, "top": 1357, "height": 49, "left": 107}, "words": "法林和其他香豆素衍生物)同时服用时应谨慎(见【药物相互作用】)"}, {"probability": {"variance": 0.001193, "average": 0.992289, "min": 0.778295}, "location": {"width": 921, "top": 1398, "height": 54, "left": 157}, "words": "大约有2.5%新诊断CML患者服用甲磺酸伊马替尼时发生严重水潴留(胸水、水肿、肺"}, {"probability": {"variance": 9e-06, "average": 0.998903, "min": 0.981759}, "location": {"width": 970, "top": 1447, "height": 52, "left": 110}, "words": "水肿、腹水和浅表浮肿),因此建议定期监测体重。应仔细评价体重的增加,必要时采取适当"}, {"probability": {"variance": 8e-06, "average": 0.998626, "min": 0.986526}, "location": {"width": 701, "top": 1500, "height": 47, "left": 112}, "words": "的支持治疗。特别是儿童患者,水潴留可能不出现可以识别的水肿"}], "language": 3}